PT  - JOURNAL ARTICLE
AU  - Markus Reindl
AU  - Kathrin Schanda
AU  - Mark Woodhall
AU  - Fiona Tea
AU  - Sudarshini Ramanathan
AU  - Jessica Sagen
AU  - James P. Fryer
AU  - John Mills
AU  - Bianca Teegen
AU  - Swantje Mindorf
AU  - Nora Ritter
AU  - Ulrike Krummrei
AU  - Winfried Stöcker
AU  - Juliane Eggert
AU  - Eoin P. Flanagan
AU  - Melanie Ramberger
AU  - Harald Hegen
AU  - Kevin Rostasy
AU  - Thomas Berger
AU  - Maria Isabel Leite
AU  - Jacqueline Palace
AU  - Sarosh R. Irani
AU  - Russell C. Dale
AU  - Christian Probst
AU  - Monika Probst
AU  - Fabienne Brilot
AU  - Sean J. Pittock
AU  - Patrick Waters
TI  - International multicenter examination of MOG antibody assays
AID  - 10.1212/NXI.0000000000000674
DP  - 2020 Mar 05
TA  - Neurology - Neuroimmunology Neuroinflammation
PG  - e674
VI  - 7
IP  - 2
4099  - http://nn.neurology.org/content/7/2/e674.short
4100  - http://nn.neurology.org/content/7/2/e674.full
SO  - Neurol Neuroimmunol Neuroinflamm2020 Mar 05; 7
AB  - Objective To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.Methods The following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG).Results We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.Conclusions Live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.ADEM=acute disseminated encephalomyelitis; AQP4=aquaporin-4; CBA=cell-based assay; FACS=fluorescence-activated cell sorting; IF=immunofluorescence; IfQ=Institute for Quality Assurance; Ig=immunoglobulin; MOG=myelin oligodendrocyte glycoprotein; NMOSD=neuromyelitis optica spectrum disorder